A study found that the 3 leading cell type therapies used to treat COVID-19 were mesenchymal stem cells or multipotent stromal cells, natural killer cells, and mononuclear cells.
Advanced cell therapies like mesenchymal stem cells or multipotent stromal cells (MSCs) could provide a clinical benefit to patients with severe COVID-19 and reduce the risk of death from the disease by 60%, according to a study published in the journal Frontiers in Immunology.1
Researchers have long sought to demonstrate the clinical efficacy of cell therapies, in particular to treat acute respiratory distress syndrome (ARDS). Previous data has shown that MSCs may be beneficial, but the onset of the COVID-19 pandemic gave researchers the opportunity to broadly study novel therapeutic interventions. However,...